Skip to main content
Show full summary

Branded Health Service Medicines (Costs) (Amendment) Regulations 2023 Lord Hunt of Kings Heath moved that this House regrets that the Branded Health Service Medicines (Costs) (Amendment) Regulations 2023 (SI 2023/239) propose a 27.5 per cent claw back rate which significantly exceeds that required by comparable countries, and which risks seriously damaging future investment in the research and development (R&D) of new drugs in the United Kingdom for the NHS, investment in the life sciences more generally, and the manufacture of branded medicines and their availability to the NHS; further regrets the short and insufficient consultation period for these measures of just 39 days over the Christmas period; and notes with concern that the UK's share of global pharmaceutical R&D has fallen by over one-third between 2012 and 2020, and that the UK’s medicine production volumes, clinical trial delivery, and global share of new medicine launches have also all declined in recent years. After debate, the motion was withdrawn.

Thursday 25 May 2023 between 13:39 and 14:42

This type of business sits within the Delegated Legislation category.

Summary

Lord Hunt of Kings Heath to move that this House regrets that the Branded Health Service Medicines (Costs) (Amendment) Regulations 2023 (SI 2023/239) propose a 27.5 per cent claw back rate which significantly exceeds that required by comparable countries, and which risks seriously damaging future investment in the research and development (R&D) of new drugs in the United Kingdom for the NHS, investment in the life sciences more generally, and the manufacture of branded medicines and their availability to the NHS; further regrets the short and insufficient consultation period for these measures of just 39 days over the Christmas period; and notes with concern that the UK's share of global pharmaceutical R&D has fallen by over one-third between 2012 and 2020, and that the UK’s medicine production volumes, clinical trial delivery, and global share of new medicine launches have also all declined in recent years. Special attention drawn to the instrument by the Secondary Legislation Scrutiny Committee, 34th Report (Lunch break business)
Legend for business item text
Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Divisions

There are no divisions to show.

Member's Registered Interests

There are no interests to show.